HUT75653A - 1,4-disubstituted piperidine derivatives acting on the glutamate receptor process for producing them and pharmaceutical compositions containing the said compounds - Google Patents

1,4-disubstituted piperidine derivatives acting on the glutamate receptor process for producing them and pharmaceutical compositions containing the said compounds Download PDF

Info

Publication number
HUT75653A
HUT75653A HU9602607A HU9602607A HUT75653A HU T75653 A HUT75653 A HU T75653A HU 9602607 A HU9602607 A HU 9602607A HU 9602607 A HU9602607 A HU 9602607A HU T75653 A HUT75653 A HU T75653A
Authority
HU
Hungary
Prior art keywords
piperidyl
ketone
fluorophenyl
naphthyloxy
propyl
Prior art date
Application number
HU9602607A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9602607D0 (en
Inventor
Andreas Huth
Graham Jones Jones
Martin Krueger
Roland Neuhaus
Eckhard Ottow
Dieter Seidelmann
Lechoslaw Turski
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HU9602607D0 publication Critical patent/HU9602607D0/hu
Publication of HUT75653A publication Critical patent/HUT75653A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU9602607A 1994-03-24 1995-03-23 1,4-disubstituted piperidine derivatives acting on the glutamate receptor process for producing them and pharmaceutical compositions containing the said compounds HUT75653A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4410822A DE4410822A1 (de) 1994-03-24 1994-03-24 Neue Piperidin-Derivate

Publications (2)

Publication Number Publication Date
HU9602607D0 HU9602607D0 (en) 1996-11-28
HUT75653A true HUT75653A (en) 1997-05-28

Family

ID=6514110

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602607A HUT75653A (en) 1994-03-24 1995-03-23 1,4-disubstituted piperidine derivatives acting on the glutamate receptor process for producing them and pharmaceutical compositions containing the said compounds

Country Status (16)

Country Link
EP (1) EP0751936A1 (de)
JP (1) JPH09510460A (de)
KR (1) KR970701695A (de)
CN (1) CN1145618A (de)
AU (1) AU2212595A (de)
CA (1) CA2186010A1 (de)
CZ (1) CZ277096A3 (de)
DE (1) DE4410822A1 (de)
FI (1) FI963786L (de)
HU (1) HUT75653A (de)
IL (1) IL113103A0 (de)
NO (1) NO963984L (de)
PL (1) PL316382A1 (de)
SK (1) SK120196A3 (de)
WO (1) WO1995025721A1 (de)
ZA (1) ZA952431B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ES2174220T3 (es) * 1996-03-08 2002-11-01 Hoffmann La Roche Uso de derivados de 4-fenil-3,6-dihidro-2h-piridilo como agentes bloqueantes de subtipos de receptores nmda.
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
EP1005348A1 (de) 1996-09-27 2000-06-07 Guilford Pharmaceuticals Inc. Naaladase zusammensetzungen und verfahren zur behandlung von glutamatabnormalien und der neuronalen aktivität in tieren
US6242450B1 (en) * 1998-07-27 2001-06-05 Eli Lilly And Company 5-HT1F antagonists
ES2221410T3 (es) * 1998-07-31 2004-12-16 Eli Lilly And Company Derivados heterociclil sulfamida.
CN1350452A (zh) * 1999-05-13 2002-05-22 盐野义制药株式会社 糖尿病的预防或治疗药
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE273953T1 (de) * 2000-03-22 2004-09-15 Hoffmann La Roche Piperidin- und pirazinverbindungen zur verwendung in der behandlung von alzheimer
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
KR102704242B1 (ko) 2017-06-20 2024-09-09 임브리아 파마슈티칼스, 인크. 심장 대사의 효율을 증가시키기 위한 조성물 및 방법
WO2020081361A1 (en) 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
CN110437136A (zh) * 2019-07-30 2019-11-12 东南大学 1-芳氧乙基哌啶-4-基苯甲酮衍生物及其制备方法和应用
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
WO1982003861A1 (fr) * 1981-05-08 1982-11-11 Tominaga Michiaki Derives d'aniline, procedes de preparation et toniques cardiaques
PH19166A (en) * 1982-09-04 1986-01-16 Pfizer Dihydropyridined,pharmaceutical compositions and method of use
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
EP0294183B1 (de) * 1987-06-02 1994-03-30 Ajinomoto Co., Inc. Verwendung von Äthylamin-Derivaten als antihypertensive Wirkstoffe
JP2779240B2 (ja) * 1987-12-11 1998-07-23 三井化学株式会社 新規アミン類およびその用途
SU1731048A3 (ru) * 1988-05-27 1992-04-30 Эйсай Ко., Лтд (Фирма) Способ получени производных пиперидина или их фармацевтически приемлемых солей
FR2632641B1 (fr) * 1988-06-13 1990-10-12 Irceba ((aryl-4-piperazinyl-1)-2 ethoxy)-3 p-cymene, les derives ortho, meta, para monosubstitues ou disubstitues sur le noyau phenyle dudit produit, le procede de preparation desdits derives, et les medicaments contenant lesdits composes comme principe actif
US5153198A (en) * 1989-03-15 1992-10-06 Santen Pharmaceutical Co., Ltd. Agent for treatment of disorders of the cerebro-neural transmission system
US5116846A (en) * 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
FR2705343B1 (fr) * 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.

Also Published As

Publication number Publication date
FI963786A7 (fi) 1996-09-23
KR970701695A (ko) 1997-04-12
JPH09510460A (ja) 1997-10-21
DE4410822A1 (de) 1995-09-28
CA2186010A1 (en) 1995-09-28
FI963786A0 (fi) 1996-09-23
MX9604201A (es) 1997-12-31
NO963984D0 (no) 1996-09-23
HU9602607D0 (en) 1996-11-28
IL113103A0 (en) 1995-06-29
WO1995025721A1 (de) 1995-09-28
EP0751936A1 (de) 1997-01-08
ZA952431B (en) 1995-12-19
CN1145618A (zh) 1997-03-19
PL316382A1 (en) 1997-01-06
AU2212595A (en) 1995-10-09
NO963984L (no) 1996-09-23
SK120196A3 (en) 1997-10-08
FI963786L (fi) 1996-09-23
CZ277096A3 (en) 1997-01-15

Similar Documents

Publication Publication Date Title
HUT75653A (en) 1,4-disubstituted piperidine derivatives acting on the glutamate receptor process for producing them and pharmaceutical compositions containing the said compounds
US5504088A (en) 2H-3,4-tetrahydroquinazoline-2-one and 2H-3,4-tetrahydroquinalozine-2,4-dione derivatives, pharmaceutical compositions and methods of treatment
US4680296A (en) Piperidine derivatives and pharmaceutical compositions containing them
WO1993014084A2 (en) Piperidine derivatives
CZ174094A3 (en) Bicyclic compound having a core formed by two conjugated six-mebered rings and a pharmaceutical preparation containing thereof
KR930001411B1 (ko) 벤즈이미다졸 유도체의 제조방법
EP0580541A1 (de) Piperidinderivate von Benzimidazole als antihistaminische und antiallergische Mittel
DK168291B1 (da) N-substituerede diphenylpiperidiner, fremgangsmåde til fremstilling deraf, lægemiddel indeholdende forbindelserne samt anvendelse af forbindelserne samt anvendelse af forbindelserne til fremstilling af et lægemiddel til anvendelse til forebyggelse eller behandling af fedme
HU195804B (en) Process for preparing piperidine derivatives and medical compositions containing them
US5314887A (en) 2-amino-1, 4-dihydropyridine derivatives with calcium agonist and alpha.sub. -antagonist activity
US4460594A (en) Bicyclo-hetero-alkylene-1-piperidines, pharmaceutical compositions thereof and methods of use thereof
US6200991B1 (en) Imidazole derivatives, preparation and therapeutic application thereof
US4560692A (en) 4-Piperidino-2-phenylquinolines
US5118691A (en) Substituted tetrahydropyridines as central nervous system agents
US5045550A (en) Substituted tetrahydropyridines as central nervous system agents
FI97131B (fi) Menetelmä terapeuttisesti aktiivisten piperidiinijohdannaisten valmistamiseksi
US5089497A (en) Substituted piperazines as central nervous system agents
EP0505465B1 (de) 4-Heterocyclyl-Piperidin Derivate, deren Herstellung und deren Verwendung als Hemmstoffe der Calcium-Akkumulation in Hirnzellen
KR20090007428A (ko) 신규 결정성 화합물
MXPA96004201A (en) New piperid derivatives
NL8105623A (nl) Nieuwe hydroxyfenyltetrahydropyridineverbindingen, hun zouten, werkwijze voor hun bereiding en tussenprodukten bij de bereiding, toepassing als geneesmiddelen en samenstelling die zij bevatten.
US5187280A (en) Substituted tetrahydropyridines and their use as central nervous system agents
US5118687A (en) 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives, pharmaceutical compositions containing them and process for preparing same
CA2170615A1 (en) Alkoxy-substituted .beta.-carbolines acting on the ampa-receptor
KR100917041B1 (ko) 5-ｈｔ7 수용체에 길항작용을 갖는 신규한 화합물

Legal Events

Date Code Title Description
DFD9 Temporary protection cancelled due to non-payment of fee